CCM
Camber Capital Management Portfolio holdings
AUM
$718M
This Quarter Return
-5.21%
1 Year Return
-4.23%
3 Year Return
+26.63%
5 Year Return
+47.71%
10 Year Return
+121.3%
AUM
$2.56B
AUM Growth
+$2.56B
(-0.71%)
Cap. Flow
+$206M
Cap. Flow
% of AUM
8.06%
Top 10 Holdings %
Top 10 Hldgs %
60.65%
Holding
41
New
8
Increased
8
Reduced
6
Closed
4
Top Buys
| 1 |
Pfizer
PFE
|
$133M |
| 2 |
Humana
HUM
|
$114M |
| 3 |
CVS Health
CVS
|
$67.3M |
| 4 |
Cigna
CI
|
$41.4M |
| 5 |
Alkermes
ALKS
|
$37.4M |
Top Sells
| 1 |
Zimmer Biomet
ZBH
|
$94.5M |
| 2 |
Globus Medical
GMED
|
$76.5M |
| 3 |
Select Medical
SEM
|
$74.1M |
| 4 |
Baxter International
BAX
|
$54.7M |
| 5 |
Universal Health Services
UHS
|
$28.6M |
Sector Composition
| 1 | Healthcare | 98.54% |
| 2 | Consumer Staples | 0.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Medtronic
MDT
$119B
| $220M | 5.08% | 2,750,000 | – | – |
|
2
Viatris
VTRS
$12.3B
| $187M | 4.32% | 15,000,000 | – | – |
|
|
3
Zimmer Biomet
ZBH
$21B
| $170M | 3.92% | 1,605,000 -895,000 | -36% | -$94.5M |
|
|
4
Humana
HUM
$36.5B
| $165M | 3.81% | 650,000 +450,000 | +225% | +$114M |
|
5
PTC Therapeutics
PTCT
$3.92B
| $144M | 3.34% | 3,200,000 -300,000 | -9% | -$13.5M |
|
6
Jazz Pharmaceuticals
JAZZ
$7.75B
| $142M | 3.28% | 1,150,000 | – | – |
|
|
7
Baxter International
BAX
$12.7B
| $135M | 3.12% | 4,625,000 -1,875,000 | -29% | -$54.7M |
|
|
8
CVS Health
CVS
$92.8B
| $135M | 3.11% | 3,000,000 +1,500,000 | +100% | +$67.3M |
|
|
9
Pfizer
PFE
$141B
| $133M | 3.07% | +5,000,000 | New | +$133M |
|
10
Sarepta Therapeutics
SRPT
$1.78B
| $122M | 2.81% | 1,000,000 +225,000 | +29% | +$27.4M |
|
11
Ascendis Pharma
ASND
$11.8B
| $110M | 2.55% | 800,000 +100,000 | +14% | +$13.8M |
|
|
12
Globus Medical
GMED
$8.27B
| $101M | 2.34% | 1,225,000 -925,000 | -43% | -$76.5M |
|
13
GSK
GSK
$79.9B
| $84.6M | 1.96% | 2,500,000 -500,000 | -17% | -$16.9M |
|
14
Brookdale Senior Living
BKD
$1.83B
| $70.1M | 1.62% | 13,935,000 | – | – |
|
|
CON
15
Concentra Group Holdings Parent, Inc.
CON
$3.05B
| $69.2M | 1.6% | 3,500,000 +1,525,000 | +77% | +$30.2M |
|
16
Qiagen
QGEN
$10.1B
| $66.8M | 1.54% | 1,500,000 | – | – |
|
17
Denali Therapeutics
DNLI
$2.23B
| $45.9M | 1.06% | 2,250,000 +250,000 | +13% | +$5.1M |
|
18
Evolent Health
EVH
$1.12B
| $45M | 1.04% | 4,000,000 +2,600,000 | +186% | +$29.3M |
|
|
19
Alkermes
ALKS
$4.78B
| $43.1M | 1% | 1,500,000 +1,300,000 | +650% | +$37.4M |
|
20
Myriad Genetics
MYGN
$593M
| $42.5M | 0.98% | 3,100,000 -850,000 | -22% | -$11.7M |
|
21
Medpace
MEDP
$13.4B
| $41.5M | 0.96% | 125,000 | – | – |
|
|
22
Cigna
CI
$80.3B
| $41.4M | 0.96% | +150,000 | New | +$41.4M |
|
23
ZimVie
ZIMV
$532M
| $38M | 0.88% | 2,725,000 | – | – |
|
24
BioMarin Pharmaceuticals
BMRN
$11.2B
| $29.6M | 0.68% | +450,000 | New | +$29.6M |
|
25
MoonLake Immunotherapeutics
MLTX
$3.54B
| $23.9M | 0.55% | 441,000 | – | – |
|